Take Part Of The Next Anti-PD1 / Anti-PD-L1 Explicyte Shuttle

06 / 29 / 2016

The comparison of the efficacy of a drug candidate with the gold standard anti-PD1 / anti-PD-L1 immunotherapy and/or evaluation of its ability to potentiate PD1/PD-L1 blockade mostly relies on immunocompetent mouse models in which the response to PD1/PD-L1 blockade has been already validated (see our recent news).

In the next explicyte shuttle, we offer our clients to include experimental groups in an already scheduled study. In this session, explicyte will cover the costs of vehicle and anti-PD1 and/or anti-PDL1 treated groups and sponsor will only cover its experimental groups (eg. drug candidates alone or in combination with anti-PD1 and/or anti-PDL1 mAbs).

The next explicyte shuttle is scheduled for the 19th of September!
 

In Vivo Syngeneic Mouse Tumor Models – CT26 And MC38 – With Differential Sensitivity To PD-1 / PD-L1 Blockade

 

  • Strain: Balb/c or C57BL/6 mice
  • Methods: Inoculation of tumor cells into immunocompetent mice
  • Readouts: Tumor growth / Body-weight / Survival
  • Standard reference : PD-1 or  PDL-1 monoclonal antibody
  • Experimental conditions: 10 animals per group
  • Turnaround time: 11-13 weeks

Experimental design in the next anti-PD1 / anti-PDL1 explicyte shuttle.  Naive balb/c or C57BL/6 immunocompetent mice are inoculated with tumor cells (CT26 or MC38) and are then exposed to anti-PD1 or anti-PDL1 monoclonal antibody at days 6, 9, 12 and 15 after inoculation. Based on this standard experimental protocol, sponsors can build different experimental groups where a drug candidate can be compared to the anti-PD1 or anti-PDL1 mAb or evaluated for its ability to synergize with the PD1 / PDL1 blocker. Efficacy study can be complemented with immune features analysis (flow cytometry, RT-qPCR) at different sites (spleen, tumor draining lymph nodes, tumor).